DAVID King compensation by year
LABCORP Summary Compensation Table · all 4 fiscal years held| Component | FY2016 | FY2017 | FY2018 | FY2019 |
|---|---|---|---|---|
| Salary | $1,133,333 | $1,150,000 | $1,175,000 | $1,215,000 |
| Bonus | $0 | $0 | $0 | — |
| Stock awards | $7,683,109 | $6,749,173 | $7,496,575 | $7,676,459 |
| Option awards | $0 | $1,581,820 | $1,819,080 | $1,799,303 |
| Non-equity incentive | $1,785,419 | $1,960,367 | $1,584,513 | $1,847,880 |
| Pension and deferred compensation | $101,810 | $128,904 | $0 | $224,723 |
| All other | $149,826 | $75,990 | $189,068 | $170,225 |
| Total | $10,853,497 | $11,646,254 | $12,264,236 | $12,933,590 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: LABCORP HOLDINGS INC. DEF 14A filed April 1, 2020, accession 0001193125-20-093549, and prior-year filings. Open the filing on EDGAR.
How this page was built: the LABCORP HOLDINGS INC. filed document, accession 0001193125-20-093549. Every figure is read from that document and cited to the page and table it appears in. Filed April 1, 2020.
Equity holdings
unvested awards at FY2019 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| PSU | 66,727 | $11,288,207 | — |
| PSU | 54,995 | $9,303,504 | — |
| PSU | 31,620 | $5,349,155 | — |
| RSU | 12,710 | $2,150,151 | — |
| RSU | 7,027 | $1,188,758 | — |
| RSU | 4,220 | $713,897 | — |
| Option | 27,334 | — | $168.49 |
| Option | 16,100 | — | $130.60 |
| Option | 52,300 | — | $146.59 |
Per the Outstanding Equity Awards at Fiscal Year-End table in LABCORP HOLDINGS INC.'s FY2019 proxy; value at the fiscal year-end close, as the company printed it.
LABCORP’s named executive officers, FY2019
as the company reported each| Named executive officer | Role | FY2019 total |
|---|---|---|
| DAVID King · this page | Former Chief Executive Officer | $12,933,590 |
| GLENN Eisenberg | Executive Vice President Chief Financial Officer | $8,822,761 |
| Adam Schechter | Chief Executive Officer | $4,617,739 |
| JOHN Ratliff | Former Executive Vice President, Chief Executive Officer of Covance Drug Development | $4,569,469 |
| Brian Caveney | Executive Vice President President, Diagnostics Chief Medical Officer | $3,479,824 |
| LANCE Berberian | Executive Vice President Chief Information and Technology Officer | $2,703,124 |
| MARK Schroeder | Executive Vice President, President Diagnostics Laboratory Operations and Global Supply Chain | $2,594,791 |
The full LABCORP compensation record
free company briefThis page is one person within LABCORP's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the LABCORP proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are LABCORP's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.